Coronary Artery Disease Clinical Trial
Official title:
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease
Polymorphisms of the cytochrome P450 (CYP) 2C19 enzyme has been consistently shown to
modulate clopidogrel response. Accordingly, the Food and Drug Administration (FDA) has issued
a warning on the potential for reduced efficacy of clopidogrel among carriers of
loss-of-function alleles (LOF) for CYP2C19 and suggest considering alternative antiplatelet
therapies for these individuals.
The pharmacodynamic (PD) effects of prasugrel and ticagrelor are not affected by CYP2C19
genetic polymorphisms. However, to date there are no head-to-head PD comparisons between
these agents among patients with different CYP2C19 genetic polymorphisms, which is currently
under investigation in CAD patients undergoing PCI at UF Health-Jacksonville (UFJ 2014-12,
NCT 02065479). In order to rule out play of chance findings, pharmacogenetic investigations
require external validation cohorts to support the study findings. Therefore, the present
randomized study is designed to serve as an external validation cohort conducted in patients
with established CAD not undergoing PCI testing the non-inferiority in platelet reactivity of
prasugrel versus ticagrelor among CYP2C19 LOF allele carriers.
Therapeutic inhibition of platelet activation is essential for the management of ischemic
cardiovascular disease. The use of platelet adenosine diphosphate (ADP) P2Y12 receptor
antagonists (clopidogrel, prasugrel, and ticagrelor) in addition to aspirin are associated
with a decrease in cardiovascular events in high-risk coronary artery disease (CAD) patients.
Clopidogrel is the most broadly utilized P2Y12 receptor antagonist. However, among
clopidogrel treated patients, there is broad variability in antiplatelet drug response which
is known carry prognostic implications. Polymorphisms of the cytochrome P450 (CYP) 2C19
enzyme has been consistently shown to modulate clopidogrel response. Accordingly, the Food
and Drug Administration (FDA) has issued a warning on the potential for reduced efficacy of
clopidogrel among carriers of loss-of-function alleles (LOF) for CYP2C19 and suggest
considering alternative antiplatelet therapies for these individuals.
The pharmacodynamic (PD) effects of prasugrel and ticagrelor are not affected by CYP2C19
genetic polymorphisms. However, to date there are no head-to-head PD comparisons between
these agents among patients with different CYP2C19 genetic polymorphisms which is currently
under investigation in CAD patients undergoing PCI at UF Health-Jacksonville (UFJ 2014-12,
NCT 02065479). In order to rule out play of chance findings, pharmacogenetic investigations
require external validation cohorts to support the study findings. Therefore, the present
randomized study is designed to serve as an external validation cohort conducted in patients
with established CAD not undergoing PCI testing the non-inferiority in platelet reactivity of
prasugrel versus ticagrelor among CYP2C19 LOF allele carriers.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
| Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
| Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
| Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
| Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
| Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
| Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
| Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
| Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
| Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
| Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
| Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
| Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
| Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
| Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
| Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
| Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions
|
N/A |